Verisante Technology, Inc. Retains Hamza Thindal Capital Corp. for Investor Relations

Verisante Technology, Inc. Retains Hamza Thindal Capital Corp. for Investor 
Relations 
VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 02/08/13 -- Verisante
Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(FRANKFURT:V3T) (the
"Company" or "Verisante"), a leader in cancer detection technology,
announced today that it has retained Hamza Thindal Capital Corp. (the
"Firm" or "Hamza Thindal") for investor relations to help broaden
investor awareness via the Firm's established network of investors in
North America, Europe and the Gulf/MENA Region. 
"We are very pleased to start working with the team at Verisante as
they enter an exciting phase of their commercialization strategy. As
a medical doctor I understand the real need for the revolutionary
products in Verisante's pipeline," said Dr. Essam Hamza MD, CEO of
Hamza Thindal. "Our unique approach, experience and successful track
record of working with development stage Health Care companies fits
very well with Verisante as the company begins full
commercialization," added Kam Thindal, President of Hamza Thindal.  
"Hamza Thindal's experience and expertise in the healthcare market is
impressive," said Thomas Braun, President & CEO of Verisante. "We are
looking forward to working with their team to increase awareness and
strengthen shareholder communication." 
The agreement with Hamza Thindal is for a one-year term that may be
terminated by either party in writing with 3 months notice. The
Company will pay a consulting fee to Hamza Thindal of $7,500 per
month plus approved expenses incurred on behalf of the Company and
has granted 300,000 share purchase options at $0.75 per share. The
options are exercisable for 24 months from the grant date and are
subject to vesting over 12 months with no more than 1/4 of the
options vesting in any three month period in accordance with TSX
Venture Policy. Both the consulting agreement and the options grant
are subject to the approval of the TSX Venture Exchange. Neither
Hamza Thindal nor any of its principals have an ownership interest,
directly or indirectly, in Verisante or its securities prior to this
agreement. 
About Verisante Technology, Inc. 
Verisante is a medical device company committed to commercializing
innovative systems for the early detection of cancer
. The Verisante
Aura(TM) for skin cancer detection and the Verisante Core(TM) series
for lung, colon and cervical cancer detection utilize a proprietary
cancer detection platform while the operating software and probe
technology are unique to each device. The cancer detection platform
was developed by the BC Cancer Agency and tested and refined at the
Skin Care Centre at Vancouver General Hospital. This exclusive
platform technology allows Verisante to develop and offer a range of
compact, non-invasive cancer detection devices that offer physicians
immediate results for many of the most common cancers. Aura(TM) has
been approved for sale in Canada, Europe and Australia. The Core(TM)
has not yet been approved for sale.  
Verisante Aura(TM) was awarded Popular Science Magazine's "Best of
What's New Award" for 2011, and awarded a 2013 Prism Award for
Innovation in Photonics. Verisante Core(TM) was named one of the top
10 cancer breakthroughs of 2011 by the Canadian Cancer Society.  
About Hamza Thindal Capital Corp. 
Hamza Thindal Capital is a Vancouver-based boutique capital markets
firm providing fundraising, investor relations (IR) and advisory to
emerging small-cap companies. The firm has the unique ability to
combine fundraising and investor relations expertise with a market
centric focus. The integration of these services provides our clients
with a long term partner as their business grows. For more
information please visit: www.htcapitalcorp.com. 
Youtube:  www.youtube.com/verisante  
Twitter: www.twitter.com/verisante  
Facebook: www.facebook.com/verisante   
Forward-Looking Statements 
This release contains forward-looking statements, including, but not
limited to, statements regarding the future commercialization of
medical devices, the market demand for these products and the
proprietary protections the Company will obtain with regard to the
technology, all of which statements are subject to market risks, and
the possibility that the Company will not be able to obtain patent
protection or obtain sufficient customer demand. These statements are
made based upon current expectations and actual results may differ
from those projected due to a number of risks and uncertainties. 
The TSX Venture Exchange has neither approved nor disapproved of the
contents of this press release. Neither the TSX Venture Exchange nor
its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this press release. 
Contacts:
Verisante Technology, Inc.
Thomas Braun
President & CEO
(604) 605-0507
info@verisante.com
www.verisante.com 
Firm Contact Information:
Hamza Thindal Capital Corp.
(604) 566-9233
info@htcapitalcorp.com
www.htcapitalcorp.com